On February 11, the AUA attended the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), where top researchers presented on new, innovative findings in the study, diagnosis and treatment of GU malignancies. Many presentations focused on health disparities in the treatment of genitourinary cancers, including a paper on the use of prostate-specific antigen velocity (PSAV) to predict how well African American men would respond to active surveillance treatment protocols. The paper found African American men were more likely to progress at lower values of PSAV and therefore merit close follow-up if they were on active surveillance. Another paper addressed the impact of telemedicine on patient-reported outcomes in urologic oncology, which found telemedicine provides a medium for cancer care delivery, which eliminates the significant travel burden associated with in-person clinical appointments.
The program included a keynote speech by Dr. William G. Kaelin, who spoke on his paper, The von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment. Dr. Kaelin’s paper focused on the concept of late mutations in a tumor being tolerated due to the mutations preceding them, and he hypothesized if this to be true, correcting early mutations should selectively kill the tumor cells. Dr. Kaelin’s paper is an incredibly exciting breakthrough in the treatment of von Hippel-Lindau disease and kidney cancer.
The AUA appreciated the chance to attend ASCO’s symposium and will continue to use these important and emerging studies in our advocacy efforts, and in our efforts to decrease health inequities and increase access to care for all.